{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:33:02Z","timestamp":1790839982476,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01883-w","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:54:10Z","timestamp":1761893650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["EZH2 suppresses the chemosensitivity of diffuse large B cell lymphoma via regulating TP53INP1"],"prefix":"10.1007","volume":"25","author":[{"given":"Jingwen","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengfei","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"issue":"10438","key":"1883_CR1","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","volume":"403","author":"E Silkenstedt","year":"2024","unstructured":"Silkenstedt E, Salles G, Campo E, Dreyling M. B-cell non-Hodgkin lymphomas. Lancet. 2024;403(10438):1791\u2013807.","journal-title":"Lancet"},{"issue":"8","key":"1883_CR2","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/ajh.27376","volume":"99","author":"A Ramirez-Gamero","year":"2024","unstructured":"Ramirez-Gamero A, Martinez-Cordero H, Beltran BE, Florindez J, Malpica L, Castillo JJ. Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99(8):1586\u201394.","journal-title":"Am J Hematol"},{"issue":"16","key":"1883_CR3","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1182\/blood.2023022432","volume":"143","author":"JL Crombie","year":"2024","unstructured":"Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil L, et al. Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy. Blood. 2024;143(16):1565\u201375.","journal-title":"Blood"},{"issue":"6","key":"1883_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","volume":"143","author":"SS Neelapu","year":"2024","unstructured":"Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024;143(6):496\u2013506.","journal-title":"Blood"},{"issue":"1","key":"1883_CR5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1158\/2159-8290.CD-23-0670","volume":"14","author":"JA Woyach","year":"2024","unstructured":"Woyach JA, Stephens DM, Flinn IW, Bhat SA, Savage RE, Chai F, et al. First-in-human study of the reversible BTK inhibitor nemtabrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma. Cancer Discov. 2024;14(1):66\u201375.","journal-title":"Cancer Discov"},{"key":"1883_CR6","doi-asserted-by":"crossref","unstructured":"Wang XW, Yang SG, Hu MW, Wang RY, Zhang C, Kosanam AR, et al. Histone methyltransferase Ezh2 coordinates mammalian axon regeneration via regulation of key regenerative pathways. J Clin Invest. 2024;134(3).","DOI":"10.1172\/JCI163145"},{"issue":"1","key":"1883_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51156-5","volume":"15","author":"VB Venkadakrishnan","year":"2024","unstructured":"Venkadakrishnan VB, Presser AG, Singh R, Booker MA, Traphagen NA, Weng K, et al. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Nat Commun. 2024;15(1):6779.","journal-title":"Nat Commun"},{"issue":"12","key":"1883_CR8","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/S1470-2045(24)00502-3","volume":"25","author":"D Maruyama","year":"2024","unstructured":"Maruyama D, Jacobsen E, Porcu P, Allen P, Ishitsuka K, Kusumoto S, et al. Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study. Lancet Oncol. 2024;25(12):1589\u2013601.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1883_CR9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","volume":"19","author":"A Italiano","year":"2018","unstructured":"Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018;19(5):649\u201359.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1883_CR10","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433\u201342.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1883_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03742-4","volume":"12","author":"E Dinh","year":"2021","unstructured":"Dinh E, Rival T, Carrier A, Asfogo N, Corti O, Melon C, et al. TP53INP1 exerts neuroprotection under ageing and Parkinson\u2019s disease-related stress condition. Cell Death Dis. 2021;12(5):460.","journal-title":"Cell Death Dis"},{"key":"1883_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.biochi.2015.07.024","volume":"118","author":"H Saadi","year":"2015","unstructured":"Saadi H, Seillier M, Carrier A. The stress protein TP53INP1 plays a tumor suppressive role by regulating metabolic homeostasis. Biochimie. 2015;118:44\u201350.","journal-title":"Biochimie"},{"issue":"1","key":"1883_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-023-04387-z","volume":"18","author":"G Li","year":"2023","unstructured":"Li G, Yan X. Long non-coding RNA GAS5 promotes cisplatin-chemosensitivity of osteosarcoma cells via microRNA-26b-5p\/TP53INP1 axis. J Orthop Surg Res. 2023;18(1):890.","journal-title":"J Orthop Surg Res"},{"issue":"2","key":"1883_CR14","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.gene.2013.12.043","volume":"538","author":"J Qin","year":"2014","unstructured":"Qin J, Luo M, Qian H, Chen W. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1. Gene. 2014;538(2):342\u20137.","journal-title":"Gene"},{"issue":"7","key":"1883_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06899-w","volume":"15","author":"Y Yang","year":"2024","unstructured":"Yang Y, Fan H, Liu H, Lou X, Xiao N, Zhang C, et al. NOP2 facilitates EZH2-mediated epithelial-mesenchymal transition by enhancing EZH2 mRNA stability via m5C methylation in lung cancer progression. Cell Death Dis. 2024;15(7):506.","journal-title":"Cell Death Dis"},{"issue":"4","key":"1883_CR16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41418-024-01271-z","volume":"31","author":"H Chen","year":"2024","unstructured":"Chen H, Yu S, Ma R, Deng L, Yi Y, Niu M, et al. Hypoxia-activated XBP1s recruits HDAC2-EZH2 to engage epigenetic suppression of DeltaNp63alpha expression and promote breast cancer metastasis independent of HIF1alpha. Cell Death Differ. 2024;31(4):447\u201359.","journal-title":"Cell Death Differ"},{"issue":"1","key":"1883_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01235-1","volume":"15","author":"S Mirzaei","year":"2022","unstructured":"Mirzaei S, Gholami MH, Hushmandi K, Hashemi F, Zabolian A, Canadas I, et al. The long and short non-coding RNAs modulating EZH2 signaling in cancer. J Hematol Oncol. 2022;15(1):18.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"1883_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01076-0","volume":"23","author":"J Longley","year":"2021","unstructured":"Longley J, Johnson PWM. Epigenetics of indolent lymphoma and how it drives novel therapeutic approaches-focus on EZH2-targeted drugs. Curr Oncol Rep. 2021;23(7):76.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"1883_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47701-x","volume":"15","author":"P Romero","year":"2024","unstructured":"Romero P, Richart L, Aflaki S, Petitalot A, Burton M, Michaud A, et al. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition. Nat Commun. 2024;15(1):3452.","journal-title":"Nat Commun"},{"key":"1883_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2024.122645","volume":"346","author":"Q Tang","year":"2024","unstructured":"Tang Q, Leng S, Tan Y, Cheng H, Liu Q, Wang Z, et al. Chitosan\/dextran-based organohydrogel delivers EZH2 inhibitor to epigenetically reprogram chemo\/immuno-resistance in unresectable metastatic melanoma. Carbohydr Polym. 2024;346:122645.","journal-title":"Carbohydr Polym"},{"issue":"9","key":"1883_CR21","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1111\/cas.15040","volume":"112","author":"K Izutsu","year":"2021","unstructured":"Izutsu K, Ando K, Nishikori M, Shibayama H, Teshima T, Kuroda J, et al. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan. Cancer Sci. 2021;112(9):3627\u201335.","journal-title":"Cancer Sci"},{"issue":"3","key":"1883_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23693","volume":"35","author":"H Ma","year":"2021","unstructured":"Ma H, Luo X, Zhou P, He N, Zhou J, Liu M, et al. USP21 promotes cell proliferation by maintaining the EZH2 level in diffuse large B-cell lymphoma. J Clin Lab Anal. 2021;35(3):e23693.","journal-title":"J Clin Lab Anal"},{"key":"1883_CR23","doi-asserted-by":"crossref","unstructured":"Beguelin W, Teater M, Meydan C, Hoehn KB, Phillip JM, Soshnev AA, et al. Mutant EZH2 Induces a pre-malignant lymphoma niche by reprogramming the immune response. Cancer Cell. 2020;37(5):655\u201373 e11.","DOI":"10.1016\/j.ccell.2020.04.004"},{"issue":"14","key":"1883_CR24","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1080\/10428194.2022.2131411","volume":"63","author":"P Wang","year":"2022","unstructured":"Wang P, Xu L, Fan Y, Li B, Chen P, Zhang X, et al. EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16. Leuk Lymphoma. 2022;63(14):3370\u20137.","journal-title":"Leuk Lymphoma"},{"key":"1883_CR25","doi-asserted-by":"crossref","unstructured":"Isshiki Y, Chen X, Teater M, Karagiannidis I, Nam H, Cai W, et al. EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. Cancer Cell. 2025;43(1):49\u201368 e9.","DOI":"10.1016\/j.ccell.2024.11.006"},{"issue":"20","key":"1883_CR26","doi-asserted-by":"publisher","first-page":"15170","DOI":"10.1021\/acs.jmedchem.1c01154","volume":"64","author":"B Zhou","year":"2021","unstructured":"Zhou B, Liang X, Mei H, Qi S, Jiang Z, Wang A, et al. Discovery of IHMT-EZH2-115 as a potent and selective enhancer of Zeste Homolog 2 (EZH2) inhibitor for the treatment of B-cell lymphomas. J Med Chem. 2021;64(20):15170\u201388.","journal-title":"J Med Chem"},{"issue":"4","key":"1883_CR27","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","volume":"13","author":"SK Knutson","year":"2014","unstructured":"Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther. 2014;13(4):842\u201354.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1883_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s12185-022-03469-8","volume":"117","author":"J Ito","year":"2023","unstructured":"Ito J, Yamagata K, Shinohara H, Shima Y, Katsumoto T, Aikawa Y, et al. Dual inhibition of EZH1\/2 induces cell cycle arrest of B cell acute lymphoblastic leukemia cells through upregulation of CDKN1C and TP53INP1. Int J Hematol. 2023;117(1):78\u201389.","journal-title":"Int J Hematol"},{"issue":"3","key":"1883_CR29","doi-asserted-by":"publisher","first-page":"530","DOI":"10.20892\/j.issn.2095-3941.2018.0380","volume":"16","author":"W Li","year":"2019","unstructured":"Li W, Bi C, Han Y, Tian T, Wang X, Bao H, et al. Targeting EZH1\/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57(CDKN1C) and TP53INP1 in mantle cell lymphoma. Cancer Biol Med. 2019;16(3):530\u201341.","journal-title":"Cancer Biol Med"},{"issue":"4","key":"1883_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1160","volume":"8","author":"D Jiang","year":"2020","unstructured":"Jiang D, Jin H, Zuo J, Kong Y, Zhang X, Dong Q, et al. Potential biomarkers screening to predict side effects of dexamethasone in different cancers. Mol Genet Genomic Med. 2020;8(4):e1160.","journal-title":"Mol Genet Genomic Med"}],"updated-by":[{"DOI":"10.1007\/s10238-025-02006-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000}}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01883-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01883-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01883-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:31:52Z","timestamp":1767677512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01883-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1883"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01883-w","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10238-025-02006-1","URL":"https:\/\/doi.org\/10.1007\/s10238-025-02006-1","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients were informed and signed informed consent voluntarily. This study was approved by the ethics committee of the First Affiliated Hospital of USTC and complied with the guidelines outlined in the declaration of Helsinki which were followed. The written consent was received from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"350"}}